These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32553501)

  • 1. The French pharmacovigilance surveys: A French distinctiveness, a real input.
    Abou Taam M; Jacquot B; Ferard C; Thery AC; Mounier C; Grandvuillemin A; Jonville-Béra AP; Perault-Pochat MC;
    Therapie; 2021; 76(5):441-447. PubMed ID: 32553501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: A win-win bet with Health Authorities!
    Jonville-Bera AP; Gautier S; Micallef J; Massy N; Atzenhoffer M; Grandvuillemin A; Drici MD;
    Therapie; 2023; 78(5):467-475. PubMed ID: 37012154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance.
    Monaco L; Melis M; Biagi C; Donati M; Sapigni E; Vaccheri A; Motola D
    Expert Opin Drug Saf; 2017 Mar; 16(3):271-275. PubMed ID: 28094583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge.
    Lacroix C; Salvo F; Gras-Champel V; Gautier S; Massy N; Valnet-Rabier MB; Grandvuillemin A; Mounier C; Benkebil M; Pariente A; Jonville-Béra AP; Micallef J;
    Therapie; 2021; 76(4):297-303. PubMed ID: 34059351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017.
    Farcaş A; Măhălean A; Bulik NB; Leucuta D; Mogoșan C
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1045-1051. PubMed ID: 30269618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the Safety of Medicines in the European Union: From Signals to Action.
    Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
    Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.
    Pacurariu AC; Coloma PM; van Haren A; Genov G; Sturkenboom MC; Straus SM
    Drug Saf; 2014 Dec; 37(12):1059-66. PubMed ID: 25398646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
    Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
    Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
    Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
    Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. French pharmacovigilance: Missions, organization and perspectives.
    Vial T
    Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
    Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B
    Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adverse drug reactions profiles for abiraterone and enzalutamide: A pharmacovigilance descriptive analysis].
    Scailteux LM; Lacroix C; Bergeron S; Despas F; Sassier M; Triquet L; Picard S; Oger E; Polard E;
    Therapie; 2021; 76(5):455-465. PubMed ID: 33376005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of drugs safety signals that predict safety related product information update.
    Insani WN; Pacurariu AC; Mantel-Teeuwisse AK; Gross-Martirosyan L
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):789-796. PubMed ID: 29797381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical adverse drug reactions: descriptive analysis of French reports.
    Hakimi Y; Petitpain N; Pinzani V; Montastruc JL; Bagheri H
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1169-1174. PubMed ID: 32418024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. French Pharmacovigilance Public System and COVID-19 Pandemic.
    Grandvuillemin A; Drici MD; Jonville-Bera AP; Micallef J; Montastruc JL;
    Drug Saf; 2021 Apr; 44(4):405-408. PubMed ID: 33372244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.